Evofem Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

Go back to Evofem Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

Evofem Biosciences (EVFM) Misses Q4 EPS by 14c

March 4, 2021 4:01 PM EST

Evofem Biosciences (NASDAQ: EVFM) reported Q4 EPS of ($0.50), $0.14 worse than the analyst estimate of ($0.36).

"2020 was a year of execution for Evofem, marked by the approval and U.S. commercial launch of Phexxi, our non-hormonal, on-demand birth control method," said Saundra Pelletier, Chief Executive... More